Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $139 | $68 | $48 | $72 |
| Short-Term Investments | $525 | $188 | $161 | $184 |
| Receivables | $58 | $42 | $43 | $42 |
| Inventory | $12 | $13 | $12 | $14 |
| Other Curr. Assets | $19 | $40 | $43 | $17 |
| Total Curr. Assets | $754 | $353 | $309 | $332 |
| Property Plant & Equip (Net) | $11 | $12 | $10 | $25 |
| Goodwill | $102 | $102 | $102 | $105 |
| Intangibles | $234 | $250 | $258 | $267 |
| Long-Term Investments | $42 | $204 | $199 | $196 |
| Tax Assets | $10 | $1 | $1 | $0 |
| Other NC Assets | $325 | $27 | $26 | $18 |
| Total NC Assets | $723 | $596 | $596 | $610 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $1,477 | $949 | $905 | $942 |
| Liabilities | – | – | – | – |
| Payables | $28 | $9 | $5 | $5 |
| Short-Term Debt | $1 | $0 | $0 | $0 |
| Tax Payable | $0 | $1 | $7 | $1 |
| Deferred Revenue | $0 | $1 | $1 | $2 |
| Other Curr. Liab. | -$1 | $40 | $29 | -$3 |
| Total Curr. Liab. | $31 | $65 | $59 | $37 |
| LT Debt | $445 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $23 | $32 | $29 | $33 |
| Other NC Liab. | $23 | $18 | $18 | $36 |
| Total NC Liab. | $496 | $55 | $51 | $74 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $6 | $6 | $4 | $7 |
| Total Liabilities | $527 | $120 | $110 | $111 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | $578 | $461 | $457 | $499 |
| AOCI | $9 | $8 | -$2 | -$6 |
| Other Equity | $363 | $0 | $0 | $0 |
| Total Equity | $950 | $829 | $796 | $830 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $1,477 | $949 | $905 | $942 |
| Net Debt | $307 | -$68 | -$48 | -$72 |